Published in Bone on March 24, 2007
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int (2010) 0.98
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int (2008) 0.91
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab (2016) 0.85
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int (2009) 0.85
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evid (2010) 0.85
A Review of Patient Preferences for Osteoporosis Drug Treatment. Curr Rheumatol Rep (2015) 0.83
Micro-morphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women. Osteoporos Int (2013) 0.83
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing. Crit Rev Eukaryot Gene Expr (2010) 0.82
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int (2016) 0.79
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence. Int J Womens Health (2015) 0.79
Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag (2007) 0.78
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int (2015) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging (2008) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Serum bone resorption markers after parathyroidectomy for renal hyperparathyroidism: correlation analyses for the cross-linked N-telopeptide of collagen I and tartrate-resistant acid phosphatase. ScientificWorldJournal (2012) 0.77
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid. Patient Prefer Adherence (2009) 0.76
Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med (2009) 0.76
Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures. Adv Orthop (2016) 0.75
Current options for the treatment of Paget's disease of the bone. Open Access Rheumatol (2009) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Ther Clin Risk Manag (2009) 0.75
Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Womens Health (2010) 0.75
Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis? Nat Clin Pract Endocrinol Metab (2008) 0.75
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int (2016) 0.75
Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int (2015) 0.75
Using Osteoporosis Therapies in Combination. Curr Osteoporos Rep (2017) 0.75
Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. Osteoporos Int (2013) 0.75
Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion. Exp Ther Med (2017) 0.75
A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int (2015) 0.75
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res (2003) 2.72
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
Natural stimuli evoke dynamic sequences of states in sensory cortical ensembles. Proc Natl Acad Sci U S A (2007) 2.11
Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits. J Bone Miner Res (2008) 2.06
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther (2007) 1.73
Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan Breast Reconstruction Outcomes Study. Ann Surg (2008) 1.47
The morphologic left ventricle that requires training by means of pulmonary artery banding before the double-switch procedure for congenitally corrected transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiovasc Surg (2008) 1.43
Phonology and reading: a response to Wang, Trezek, Luckner, and Paul. Am Ann Deaf (2009) 1.42
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Menopause (2011) 1.40
Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res (2006) 1.32
Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet (2010) 1.31
Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr (2003) 1.29
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol (2013) 1.27
Heterogenous population coding of a short-term memory and decision task. J Neurosci (2010) 1.24
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab (2013) 1.21
Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Am J Epidemiol (2002) 1.20
Sooner and healthier: a randomised controlled trial and interview study of an early discharge rehabilitation service for older people. Age Ageing (2004) 1.20
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
A randomised controlled trial of a care home rehabilitation service to reduce long-term institutionalisation for elderly people. Age Ageing (2004) 1.15
Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. Am J Clin Nutr (2010) 1.14
Body odor similarity in noncohabiting twins. Chem Senses (2005) 1.13
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A (2006) 1.13
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res (2007) 1.12
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res (2006) 1.04
Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. J Bone Miner Res (2007) 1.03
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol Cancer Ther (2005) 1.02
Phosphorothioate oligonucleotides block the VDAC channel. Biophys J (2007) 1.01
The spectrum of paediatric cardiac disease presenting to an outpatient clinic in Malawi. BMC Res Notes (2013) 1.01
Bone material properties in premenopausal women with idiopathic osteoporosis. J Bone Miner Res (2012) 1.00
Midterm results after restoration of the morphologically left ventricle to the systemic circulation in patients with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg (2003) 1.00
Innominate venous aneurysm presenting as a rapidly expanding mediastinal mass. Ann Thorac Surg (2007) 0.99
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res (2011) 0.97
G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Clin Cancer Res (2009) 0.96
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res (2004) 0.95
Synaptic plasticity and connectivity requirements to produce stimulus-pair specific responses in recurrent networks of spiking neurons. PLoS Comput Biol (2011) 0.95
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 0.95
Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. J Nutr (2007) 0.94
Excitatory, inhibitory, and structural plasticity produce correlated connectivity in random networks trained to solve paired-stimulus tasks. Front Comput Neurosci (2011) 0.93
Effects of degraded sensory input on memory for speech: behavioral data and a test of biologically constrained computational models. Brain Res (2010) 0.93
Modulation of Golgi-associated microtubule nucleation throughout the cell cycle. Cytoskeleton (Hoboken) (2012) 0.93
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res (2004) 0.92
Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol (2009) 0.92
Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy. Bone (2010) 0.92
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res (2004) 0.92
Cooled transurethral microwave thermotherapy for intractable chronic prostatitis--results of a pilot study after 1 year. Urology (2004) 0.91
Influence of nitrogen fertilization on xylem traits and aquaporin expression in stems of hybrid poplar. Tree Physiol (2010) 0.91
Intrahepatic cholangiocarcinoma presenting as the Budd-Chiari syndrome: a case report and literature review. Can J Gastroenterol (2005) 0.90
Quantitative ultrasound: use in screening for susceptibility to stress fractures in female army recruits. J Bone Miner Res (2004) 0.89
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study. Eur J Nutr (2013) 0.89
The use of physical assessment skills by registered nurses in Australia: issues for nursing education. Collegian (2013) 0.88
The influence of pulmonary artery morphology on the results of operations for major aortopulmonary collateral arteries and complex congenital heart defects. J Thorac Cardiovasc Surg (2004) 0.87
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis (2007) 0.86
Infant mortality and air pollution: modifying effect by social class. J Occup Environ Med (2004) 0.86
Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration. Hum Gene Ther (2012) 0.86
Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP. Am J Physiol Cell Physiol (2006) 0.86
Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev (2016) 0.86
Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J Proteome Res (2010) 0.85
Aging and luteinizing hormone effects on reactive oxygen species production and DNA damage in rat Leydig cells. Biol Reprod (2013) 0.85
Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain. Protein J (2013) 0.85
A novel telemonitoring device for improving diabetes control: protocol and results from a randomized clinical trial. Telemed J E Health (2014) 0.85
Modeling the atmospheric transport and deposition of mercury to the Great Lakes. Environ Res (2004) 0.84
Transmenopausal changes in trabecular bone quality. J Bone Miner Res (2014) 0.84
Gene targeting by triple helix-forming oligonucleotides. Ann N Y Acad Sci (2003) 0.83
Investigation of H7N2 avian influenza outbreaks in two broiler breeder flocks in Pennsylvania, 2001-02. Avian Dis (2004) 0.82
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials. J Womens Health (Larchmt) (2008) 0.82
Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Clin Cancer Res (2004) 0.82
Washoff of cypermethrin residues from slabs of external building material surfaces using simulated rainfall. Environ Toxicol Chem (2013) 0.82
Acoustic masking disrupts time-dependent mechanisms of memory encoding in word-list recall. Mem Cognit (2014) 0.81
One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. Curr Med Res Opin (2010) 0.80
Influence of surgical strategies on outcome after the Norwood procedure. J Thorac Cardiovasc Surg (2006) 0.80
Assessment of the optical radiation hazard from a home-use intense pulsed light (IPL) source. Lasers Surg Med (2009) 0.80
Thyroid hormone use and the risk of hip fracture in women > or = 65 years: a case-control study. J Womens Health (Larchmt) (2003) 0.79
Surgical aortic valvotomy in infancy: impact of leaflet morphology on long-term outcomes. Ann Thorac Surg (2003) 0.79
Facial palsy as a presenting feature of coarctation of aorta. Interact Cardiovasc Thorac Surg (2003) 0.79
Dynamic afferent synapses to decision-making networks improve performance in tasks requiring stimulus associations and discriminations. J Neurophysiol (2012) 0.79
Porcine sperm bind to specific 6-sialylated biantennary glycans to form the oviduct reservoir. Biol Reprod (2012) 0.79
Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors. J Invest Dermatol (2005) 0.78
[Infant morbidity caused by respiratory diseases and its relation with the air pollution in Juarez City, Chihuahua, Mexico]. Salud Publica Mex (2007) 0.78
Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells. Bioconjug Chem (2002) 0.78
Proteomics in bone research. Expert Rev Proteomics (2010) 0.78
Benefits of predischarge echocardiography service for postnatal heart murmurs. Acta Paediatr (2012) 0.78
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int (2004) 0.77
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcif Tissue Int (2012) 0.76
Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency. Mol Ther (2007) 0.76
The teaching of physical assessment skills in pre-registration nursing programmes in Australia: issues for nursing education. Collegian (2014) 0.76
Experience with intraoperative ultrasound in paediatric cardiac surgery. Cardiol Young (2006) 0.75
Contract for UK consultants. Lancet (2003) 0.75
Toxic anterior segment syndrome and are we missing it? Vet Ophthalmol (2009) 0.75
Surgical management of hypoplastic left heart syndrome at the Birmingham Children's Hospital. Multimed Man Cardiothorac Surg (2009) 0.75
Acute interventions for stenosed right ventricle-pulmonary artery conduit following the right-sided modification of Norwood-Sano procedure. Congenit Heart Dis (2009) 0.75